tetano
Editor, Senior Moderator
PLoS One. 2015 Jan 30;10(1):e0117822. doi: 10.1371/journal.pone.0117822. eCollection 2015.
[h=1]Molecular Surveillance of Antiviral Drug Resistance of Influenza A/H3N2 Virus in Singapore, 2009-2013.[/h] Lee HK[SUP]1[/SUP], Tang JW[SUP]2[/SUP], Loh TP[SUP]3[/SUP], Hurt AC[SUP]4[/SUP], Oon LL[SUP]5[/SUP], Koay ES[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Adamantanes and neuraminidase inhibitors (NAIs) are two classes of antiviral drugs available for the chemoprophylaxis and treatment of influenza infections. To determine the frequency of drug resistance in influenza A/H3N2 viruses in Singapore, large-scale sequencing of neuraminidase (NA) and matrix protein (MP) genes was performed directly without initial culture amplification. 241 laboratory-confirmed influenza A/H3N2 clinical samples, collected between May 2009 and November 2013 were included. In total, 229 NA (95%) and 241 MP (100%) complete sequences were obtained. Drug resistance mutations in the NA and MP genes were interpreted according to published studies. For the NAIs, a visual inspection of the aligned NA sequences revealed no known drug resistant genotypes (DRGs). For the adamantanes, the well-recognised S31N DRG was identified in all 241 MP genes. In addition, there was an increasing number of viruses carrying the combination of D93G+Y155F+D251V (since May 2013) or D93G (since March 2011) mutations in the NA gene. However, in-vitro NAI testing indicated that neither D93G+Y155F+D251V nor D93G alone conferred any changes in NAI susceptibility. Lastly, an I222T mutation in the NA gene that has previously been reported to cause oseltamivir-resistance in influenza A/H1N1/2009, B, and A/H5N1, was detected from a treatment-na?ve patient. Further in-vitro NAI testing is required to confirm the effect of this mutation in A/H3N2 virus.
PMID: 25635767 [PubMed - in process] Free full text
[h=1]Molecular Surveillance of Antiviral Drug Resistance of Influenza A/H3N2 Virus in Singapore, 2009-2013.[/h] Lee HK[SUP]1[/SUP], Tang JW[SUP]2[/SUP], Loh TP[SUP]3[/SUP], Hurt AC[SUP]4[/SUP], Oon LL[SUP]5[/SUP], Koay ES[SUP]1[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] Adamantanes and neuraminidase inhibitors (NAIs) are two classes of antiviral drugs available for the chemoprophylaxis and treatment of influenza infections. To determine the frequency of drug resistance in influenza A/H3N2 viruses in Singapore, large-scale sequencing of neuraminidase (NA) and matrix protein (MP) genes was performed directly without initial culture amplification. 241 laboratory-confirmed influenza A/H3N2 clinical samples, collected between May 2009 and November 2013 were included. In total, 229 NA (95%) and 241 MP (100%) complete sequences were obtained. Drug resistance mutations in the NA and MP genes were interpreted according to published studies. For the NAIs, a visual inspection of the aligned NA sequences revealed no known drug resistant genotypes (DRGs). For the adamantanes, the well-recognised S31N DRG was identified in all 241 MP genes. In addition, there was an increasing number of viruses carrying the combination of D93G+Y155F+D251V (since May 2013) or D93G (since March 2011) mutations in the NA gene. However, in-vitro NAI testing indicated that neither D93G+Y155F+D251V nor D93G alone conferred any changes in NAI susceptibility. Lastly, an I222T mutation in the NA gene that has previously been reported to cause oseltamivir-resistance in influenza A/H1N1/2009, B, and A/H5N1, was detected from a treatment-na?ve patient. Further in-vitro NAI testing is required to confirm the effect of this mutation in A/H3N2 virus.
PMID: 25635767 [PubMed - in process] Free full text